Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Financial sector's mixed performance amid economic uncertainty, with some firms facing challenges while others demonstrate resilience through digital transformation and shareholder returns.
Authorities detain seven, charge four in daring Louvre jewel heist that remains unsolved.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Financial sector's mixed performance amid economic uncertainty, with some firms facing challenges while others demonstrate resilience through digital transformation and shareholder returns.
Authorities detain seven, charge four in daring Louvre jewel heist that remains unsolved.